|Molecular biology and targeted therapy of cutaneous T-cell lymphomas.|
|PMID: 19169209 Owner: NLM Status: MEDLINE|
|Cutaneous T-cell lymphoma (CTCL) is an extra-nodal non-Hodgkin lymphoma of mature T cells. These tumor cells home to and persist in the skin, producing a broad spectrum of clinical entities. Recent results of basic research on tumor biology and tumor immunology as well as molecular genetics of cutaneous T-cell lymphoma have fostered the development of new therapeutic approaches. Several clinical trials testing these targeted therapies have shown encouraging results. This article provides an overview of recent research developments and therapeutic strategies for cutaneous T-cell lymphoma.|
|C D Klemke; S Goerdt|
Related Documents :
|15279579 - Mechanism targeted discovery of antitumor marine natural products.
19245809 - Erk and pi3k regulate different aspects of the epithelial to mesenchymal transition of ...
15095259 - Molecular markers of radiation effectiveness in head and neck squamous cell carcinoma.
16224119 - A single-cell-based model of tumor growth in vitro: monolayers and spheroids.
19064739 - Stem cell concepts renew cancer research.
20141219 - Molecular analysis of tumor margins by maldi mass spectrometry in renal carcinoma.
9924699 - Combined cytotoxic effects of tumor necrosis factor-alpha with various cytotoxic agents...
21121739 - A cortical dysembryoplastic neuroepithelial tumor initially occurring in the periventri...
17328069 - The number of regulatory t cells in prostate cancer is associated with the androgen rec...
|Type: Journal Article; Review|
|Title: Giornale italiano di dermatologia e venereologia : organo ufficiale, Società italiana di dermatologia e sifilografia Volume: 143 ISSN: 0392-0488 ISO Abbreviation: G Ital Dermatol Venereol Publication Date: 2008 Dec|
|Created Date: 2009-01-26 Completed Date: 2009-04-03 Revised Date: 2013-06-03|
Medline Journal Info:
|Nlm Unique ID: 8102852 Medline TA: G Ital Dermatol Venereol Country: Italy|
|Languages: eng Pagination: 365-74 Citation Subset: IM|
|Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karls-University of Heidelberg, Mannheim, Germany. firstname.lastname@example.org|
|APA/MLA Format Download EndNote Download BibTex|
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm / therapeutic use
Antigens, Differentiation, T-Lymphocyte
Antigens, Neoplasm / immunology
Antineoplastic Agents / administration & dosage, adverse effects, therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
CD4-Positive T-Lymphocytes / immunology*
Clinical Trials as Topic
Cytokines / immunology
Dendritic Cells / immunology
Diphtheria Toxin / therapeutic use
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Histone Deacetylase Inhibitors
Hydroxamic Acids / therapeutic use
Interleukin-2 / therapeutic use
Keratinocytes / immunology
Lymphoma, T-Cell / drug therapy*, genetics, immunology*
Macrophages / immunology
Mast Cells / immunology
Membrane Glycoproteins / immunology
NF-kappa B / immunology
Receptors, Chemokine / immunology
Recombinant Fusion Proteins / therapeutic use
Skin Neoplasms / drug therapy*, genetics, immunology*
Tetrahydronaphthalenes / therapeutic use
Tumor Markers, Biological / immunology
|0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antibodies, Neoplasm; 0/Antigens, Differentiation, T-Lymphocyte; 0/Antigens, Neoplasm; 0/Antineoplastic Agents; 0/CTAGE1 protein, human; 0/Cytokines; 0/Diphtheria Toxin; 0/Histone Deacetylase Inhibitors; 0/Hydroxamic Acids; 0/Interleukin-2; 0/Membrane Glycoproteins; 0/NF-kappa B; 0/Receptors, Chemokine; 0/Recombinant Fusion Proteins; 0/Tetrahydronaphthalenes; 0/Tumor Markers, Biological; 0/bexarotene; 0/zanolimumab; 149647-78-9/vorinostat; 25E79B5CTM/denileukin diftitox; 3A189DH42V/alemtuzumab|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Granuloma annulare.
Next Document: Immunopathogenesis of mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma).